130 related articles for article (PubMed ID: 12683663)
1. In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres.
Espuelas MS; Legrand P; Loiseau PM; Bories C; Barratt G; Irache JM
J Drug Target; 2002 Dec; 10(8):593-9. PubMed ID: 12683663
[TBL] [Abstract][Full Text] [Related]
2. The effect of amphotericin b derivatives on Leishmania and immune functions.
Ehrenfreund-Kleinman T; Domb AJ; Jaffe CL; Nasereddin A; Leshem B; Golenser J
J Parasitol; 2005 Feb; 91(1):158-63. PubMed ID: 15856892
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
Larabi M; Yardley V; Loiseau PM; Appel M; Legrand P; Gulik A; Bories C; Croft SL; Barratt G
Antimicrob Agents Chemother; 2003 Dec; 47(12):3774-9. PubMed ID: 14638481
[TBL] [Abstract][Full Text] [Related]
4. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
Prajapati VK; Awasthi K; Gautam S; Yadav TP; Rai M; Srivastava ON; Sundar S
J Antimicrob Chemother; 2011 Apr; 66(4):874-9. PubMed ID: 21393222
[TBL] [Abstract][Full Text] [Related]
5. Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani.
Dikhit MR; Purkait B; Singh R; Sahoo BR; Kumar A; Kar RK; Ansari MY; Saini S; Abhishek K; Sahoo GC; Das S; Das P
Drug Des Devel Ther; 2016; 10():1753-61. PubMed ID: 27307706
[TBL] [Abstract][Full Text] [Related]
6. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
7. In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188.
Espuelas S; Legrand P; Loiseau PM; Bories C; Barratt G; Irache JM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2190-2. PubMed ID: 10898700
[TBL] [Abstract][Full Text] [Related]
8. N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.
Nicoletti S; Seifert K; Gilbert IH
Int J Antimicrob Agents; 2009 May; 33(5):441-8. PubMed ID: 19097763
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.
Kumar P; Shivam P; Mandal S; Prasanna P; Kumar S; Prasad SR; Kumar A; Das P; Ali V; Singh SK; Mandal D
Int J Nanomedicine; 2019; 14():6073-6101. PubMed ID: 31686803
[TBL] [Abstract][Full Text] [Related]
10. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
13. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles.
Jain V; Gupta A; Pawar VK; Asthana S; Jaiswal AK; Dube A; Chourasia MK
Appl Biochem Biotechnol; 2014 Oct; 174(4):1309-1330. PubMed ID: 25106894
[TBL] [Abstract][Full Text] [Related]
15. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
16. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.
Singh PK; Pawar VK; Jaiswal AK; Singh Y; Srikanth CH; Chaurasia M; Bora HK; Raval K; Meher JG; Gayen JR; Dube A; Chourasia MK
Int J Biol Macromol; 2017 Dec; 105(Pt 1):1220-1231. PubMed ID: 28780414
[TBL] [Abstract][Full Text] [Related]
17. Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B.
Pandya S; Verma RK; Khare P; Tiwari B; Srinivasarao DA; Dube A; Goyal N; Misra A
Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):125-32. PubMed ID: 27183429
[TBL] [Abstract][Full Text] [Related]
18. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.
Manandhar KD; Yadav TP; Prajapati VK; Basukala O; Aganja RP; Dude A; Shrivastav ON; Sundar S
Adv Exp Med Biol; 2014; 808():77-91. PubMed ID: 24595612
[TBL] [Abstract][Full Text] [Related]
19. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.
Gupta PK; Jaiswal AK; Kumar V; Verma A; Dwivedi P; Dube A; Mishra PR
Mol Pharm; 2014 Mar; 11(3):951-63. PubMed ID: 24495144
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis.
Italia JL; Kumar MN; Carter KC
J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
